GLP-1 weight loss and muscle
Weight lost during GLP-1 treatment is not all fat. DXA substudies of semaglutide and tirzepatide measured decreases in both fat and lean mass. Lean mass is not the same as muscle: it includes other non-fat tissue. The joint nutrition advisory pairs adequate protein with strength training rather than treating protein alone as enough.
What the body-composition studies measured
Swipe or scroll sideways to compare all columns.
| Study | Participants / duration | Active treatment: fat / lean change | Placebo: fat / lean change |
|---|---|---|---|
| STEP 1 exploratory DXA abstract | 140 / 68 weeks | −19.3% / −9.7% | Not numerically extracted from this abstract |
| SURMOUNT-1 DXA substudy | 160 / 72 weeks | −33.9% / −10.9% | −8.2% / −2.6% |
Ten percent of what?
The table reports change from the baseline amount of each tissue. A 10.9% reduction in lean mass is not “10.9% of the weight lost was muscle.” SURMOUNT-1 separately reports that about 25% of the lost weight was lean mass in both groups. Those are different denominators, and neither directly measures strength.
Why these rows are not a drug ranking
STEP 1 and SURMOUNT-1 were separate studies with different durations and participants. The SURMOUNT-1 DXA result pools tirzepatide doses; the STEP 1 material here is an exploratory conference abstract. The rows help interpret each study, not establish that one drug preserves more muscle than the other.
Where protein fits
The four-society advisory says increased protein alone is likely inadequate without structured resistance training. This is nutrition and activity guidance, not evidence that a particular shake prevents muscle loss. The companion tool separates that guidance from the still-recruiting creatine trial.
Registered studies, and how many reached Phase 3
Light bar: registered studies. Dark bar: those that reached Phase 3. ClinicalTrials.gov API v2, counted 7 September 2026.
How much of the GLP-1 trial programme looks at muscle
Swipe or scroll sideways to compare all columns.
| Studies counted | Registered | Reached Phase 3 |
|---|---|---|
| All GLP-1 receptor agonist studies | 1,668 | 356 |
| Those that also name muscle, lean mass or sarcopenia | 108 | 8 |
| Those that also name resistance training | 21 | 2 |
| Bimagrumab, an antibody aimed at muscle mass | 17 | 3 |
| Sarcopenia, all interventions | 2,036 | 42 |
Six percent of the programme measures it
Counted on 7 September 2026, ClinicalTrials.gov held 1,668 registered studies of GLP-1 receptor agonists, and 356 of them had reached Phase 3. Studies that also name muscle, lean mass or sarcopenia number 108, of which 8 reached Phase 3. The question people ask most about these drugs is addressed in roughly one study in fifteen, and in about one late-phase study in forty-five. A registered study is a declaration of intent, not a result.
What is actually being tested alongside the drug
Twenty-one registered studies combine a GLP-1 drug with resistance training or resistance exercise, and two of those reached Phase 3. That is the intervention the four-society advisory points to, and it is the smallest column in the table. Bimagrumab, an antibody developed to act on muscle mass directly, carries 17 registered studies with 3 at Phase 3. For scale, sarcopenia across every intervention carries 2,036 studies with 42 at Phase 3.
Repeat these registry counts yourself
The counts come from the ClinicalTrials.gov API v2 on 7 September 2026, using query.term for each row and the Phase 3 filter for the second column. The muscle row searches semaglutide, tirzepatide or GLP-1 receptor agonist together with lean mass, muscle mass, sarcopenia or skeletal muscle. The training row swaps those for resistance training or resistance exercise. Each captured response is stored with its own checksum, so the same query can be run again and compared.
Use the table and its sources
Related reading
CompareOrforglipron vs oral semaglutide
Orforglipron lowered HbA1c more than oral semaglutide in ACHIEVE-3, but gastrointestinal events were more frequent.
CompareRetatrutide vs tirzepatide
Tirzepatide targets GIP and GLP-1 receptors; retatrutide also targets the glucagon receptor.
ReadCreatine with GLP-1: the trial
Creatine during GLP-1 treatment is being tested directly.
ReadVitamins during GLP-1 treatment
There is no single vitamin stack in the joint nutrition advisory for everyone taking a GLP-1 medicine.
ReadGLP-1 treatment and hair shedding
Hair loss is reported in the Zepbound trials, and its label associates those reactions with weight reduction.
Source-linked editorial synthesis, prepared with AI assistance. This is not a clinician review or a personalised treatment recommendation. Corrections: editorial standards.